Susquehanna International Group
CBIO

Susquehanna International Group’s Crescent Biopharma CBIO Stock Holding History

Susquehanna International Group’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-219
Closed -$4.6K – 13035
2025
Q1 		$4.6K Buy
+219
New +$5.86K ﹤0.01% 12262
2024
Q3 		– Sell
-11,702
Closed -$328K – 12362
2024
Q2 		$328K Buy
11,702
+8,076
+223% +$840K ﹤0.01% 9246
2024
Q1 		$1.09M Buy
3,626
+2,963
+447% +$885K ﹤0.01% 6690
2023
Q4 		$156K Sell
663
-1,652
-71% -$257K ﹤0.01% 10934
2023
Q3 		$347K Buy
2,315
+1,258
+119% +$198K ﹤0.01% 9038
2023
Q2 		$184K Buy
1,057
+400
+61% +$67.1K ﹤0.01% 10364
2023
Q1 		$82.8K Buy
657
+400
+156% +$90K ﹤0.01% 11413
2022
Q4 		$77.9K Buy
+257
New +$37.9K ﹤0.01% 11146
2022
Q3 		– Sell
-614
Closed -$37K – 13532
2022
Q2 		$37K Sell
614
-298
-33% -$22.1K ﹤0.01% 12128
2022
Q1 		$104K Buy
912
+544
+148% +$63.8K ﹤0.01% 11874
2021
Q4 		$53K Sell
368
-411
-53% -$74.6K ﹤0.01% 12512
2021
Q3 		$171K Sell
779
-692
-47% -$147K ﹤0.01% 11658
2021
Q2 		$341K Buy
1,471
+1,347
+1,086% +$343K ﹤0.01% 10490
2021
Q1 		$37K Buy
+124
New +$44.4K ﹤0.01% 12088
2020
Q4 		– Sell
-178
Closed -$55K – 11265
2020
Q3 		$55K Buy
178
+68
+62% +$26K ﹤0.01% 10178
2020
Q2 		$41K Buy
+110
New +$31.1K ﹤0.01% 9800
2019
Q2 		– Sell
-174
Closed -$217K – 10437
2019
Q1 		$217K Buy
+174
New +$199K ﹤0.01% 7761
2018
Q4 		– Sell
-346
Closed -$498K – 9296
2018
Q3 		$498K Sell
346
-448
-56% -$678K ﹤0.01% 6539
2018
Q2 		$1.28M Sell
794
-2,413
-75% -$4.15M ﹤0.01% 4839
2018
Q1 		$5.21M Buy
3,207
+2,826
+742% +$5.88M ﹤0.01% 2499
2017
Q4 		$640K Buy
+381
New +$504K ﹤0.01% 6141

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Susquehanna International Group's CBIO Position: Q1 2026 in Review

Susquehanna International Group increased its Crescent Biopharma (CBIO) stake by 274% in Q1 2026, buying an estimated $1.8M and bringing the position to 213,635 shares worth $3.92M. The position accounts for ﹤0.01% of the portfolio, ranked #4707.

Susquehanna International Group first reported a position in CBIO in Q2 2017 and has held it in 26 quarters since. 63 funds tracked by Wall St. Rank hold CBIO as of Q1 2026.

  • Susquehanna International Group held 213,635 shares of Crescent Biopharma worth $3.92M as of Q1 2026.
  • Susquehanna International Group bought 156,587 Crescent Biopharma shares in Q1 2026, an estimated $1.8M.
  • Crescent Biopharma made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #4707 holding.
  • Susquehanna International Group first reported a position in Crescent Biopharma in Q2 2017 and has held it in 26 quarters since.
  • 63 funds tracked by Wall St. Rank held Crescent Biopharma as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.